echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > First immunotherapy for esophageal cancer (ESCC)! Best-in-the-hundred Opdivo approved by the European Union: second-line treatment significantly extends survival!

    First immunotherapy for esophageal cancer (ESCC)! Best-in-the-hundred Opdivo approved by the European Union: second-line treatment significantly extends survival!

    • Last Update: 2020-12-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    It's worth noting that at the end of July 2019, the Merca East PD-1 oncology immunotherapy Keytruda (Nerida, common name: pembrolizumab, Pabli Pearl Mono-Resistance) was awarded FDA approved the treatment of patients with PD-L1-positive esophageal squamous cell carcinoma (ESCC), specifically: patients with tumor expression PD-L1 (combined positive score (CPS) ≥10), relapsed, localized late stage, or metastatic ESCC patients with disease progression after receiving one or more systemic therapies.
    Keytruda is the first anti-PD-1 therapy approved for the treatment of patients with relapsed localized late stage or metastasis ESCC (tumor expression PD-L1, CPS≥10).
    this approval is based on data from 2 clinical studies, KEYNOTE-181 (NCT02564263) and KEYNOTE-180 (NCT02559687).
    data from the KEYNOTE-181 study show that in patients with ESCC tumor expression PD-L1 (CPS≥10), keytruda treated patients with OS showed an improvement compared to chemotherapy patients (medium OS: 10.3 months. 7.0-13.5' vs 6.7 months (95%CI: 4.8-8.6) and HR=0.64 (95% CI: 0.46-0.90) ).
    ESCC patients with 35 tumor expression PD-L1 (CPS≥10) had ANR of 20% (95% CI: 8.0, 37.0), according to data from the KEYNOTE-180 study.
    7 patients with remission, DOR ranged from 4.2 months to 25.1 plus months, 71% of patients (5 cases≥ DOR≥6 months, 57% of patients (3 cases≥ DOR≥12 months.
    Origin: Bristol Myers Squibb Receives European Commission approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.